Risk factors of cycle acceleration in acutely admitted patients with bipolar disorder. (24th June 2014)

• Record Type: Journal Article
• Authors: Finseth, P. I.; Morken, G.; Malt, U. F.; Andreassen, O. A.; Vaaler, A. E.
• Is Part Of: Acta psychiatrica Scandinavica. Volume 130:Number 5(2014:Nov.)
• Page Start: 388
• Page End: 396
• Publication Date: 2014-06-24
• Subjects: Psychiatry -- Periodicals; 616.89
• DOI: 10.1111/acps.12308
• Languages: English
• ISSNs: 0001-690X

Abstract

<abstract abstract-type="main" id="acps12308-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="acps12308-sec-0001" sec-type="section"> <title>Objective</title> <p>To identify risk factors associated with cycle acceleration (CA), that is, progressive decrease in duration of syndrome‐free intervals between affective episodes, in acutely admitted patients with bipolar disorder (BD).</p> </sec> <sec id="acps12308-sec-0002" sec-type="section"> <title>Method</title> <p>All patients (<italic>n</italic> = 210) with BD I (67%) and BD II (33%) (DSM‐IV) acutely admitted to a hospital serving a catchment area were compared in retrospect with regard to a positive or negative history of CA. Putative risk factors of CA with a <italic>P</italic>‐value <0.05 in uni‐variate tests were secondly entered into a logistic regression model.</p> </sec> <sec id="acps12308-sec-0003" sec-type="section"> <title>Results</title> <p>The logistic regression model was statistically significant (<italic>P</italic> < 0.0001) and explained between 45.3% and 60.5% of the variance of CA status. 83.7% of the cases were correctly classified with a sensitivity of 87.2% and a specificity of 80.4%. Unique significant risk factors of CA were increasing severity of affective episodes (odds ratio (OR) = 28.8), BD II (OR = 3.3), hypomanic/manic episode induced by an antidepressant and/or alcohol (OR = 3.3), and female gender (OR = 3.1).</p> </sec> <sec id="acps12308-sec-0004" sec-type="section"> <title>Conclusion</title> <p>The clinical factors associated with CA may help targeting patients with BD with a course aggravation, and are in line with previously reported neuropathological processes of illness progression.</p> </sec> </abstract>